AzTrials
AzTrials

Multiple SclerosisMSNCT07434934

Augmented Reality-Based Dual-Task Training in People With Multiple Sclerosis

A study testing Augmented Reality Exercises in people with Multiple Sclerosis, run by University of Sharjah at 1 site in United Arab Emirates.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Multiple Sclerosis (MS) is the most common NDD affecting young people worldwide. MS can seriously affect quality of life and hinder daily functional activities. Therefore, living with MS is a daunting task for both patients and their families. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Multiple Sclerosis
What is being tested?
Augmented Reality Exercises
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteUnited Arab Emirates
Study dates
1 Aug 2026to 1 Sep 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Neurologist-confirmed diagnosis of MS according to the revised McDonald criteria and PDDS score of ≤6
  • Age above 18 years;
  • Affected by relapsing remitting and secondary progressive MS
  • Successful completion of Physical Activity Readiness Questionnaire (PAR-Q)
  • Presence of mild/moderate cognitive impairment (Montreal Cognitive Assessment - MoCA >18)
  • Ambulatory for indoor and outdoor mobility with or without an assistive device but without physical assistance

Who cannot join

  • Acute illness or injury that would prevent safe participation in an exercise program
  • Presence of any other neurological conditions (e.g., stroke),
  • Presence of severe psychiatric illness other than anxiety or depression
  • According to the Diagnostic and Statistical Manual of Mental Disorders, 5th -Edition (DSM- V),
  • Presence of disabling sensory alterations (i.e. auditory and visual disturbances)
  • Relapse in the 3 months before enrollment
  • Current engagement in 3 days a week or more of moderate/vigorous exercise

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Alham Al Sharman, Associate Prof contact

00971563103259

aal-sharman@sharjah.ac.ae

United Arab Emirates1 site
  • Alham Al Sharman

    Sharjah city, Emirate of Sharjah, 27272

    Alham Al Sharman, Associate Prof, 00971563103259, aal-sharman@sharjah.ac.ae

Other trials in United Arab Emirates

About this study

Official title: Development of Augmented Reality-Based Dual-Task Training to Enhance Cognitive and Motor Function in People With Multiple Sclerosis

Multiple Sclerosis (MS) is the most common NDD affecting young people worldwide. MS can seriously affect quality of life and hinder daily functional activities. Therefore, living with MS is a daunting task for both patients and their families. With the prediction of an increase in life expectancy, it is also expected that MS will pose major challenges to healthcare providers in the UAE and globally in terms of its clinical management and financial implications. This proposed project aims to develop structured AR scenarios that integrate dual-tasking exercises commonly used in MS physiotherapy, specifically designed to meet the needs of PwMS. The primary goal is to evaluate the feasibility, acceptability, and potential benefits of these AR scenarios as a rehabilitation tool for PwMS.

Read the detailed description

Among the most concerning aspects of MS are the presence of gait impairments, balance deficits, and cognitive dysfunction. These symptoms become even more pronounced under dual-task conditions. Dual tasks require individuals to perform cognitive and motor tasks simultaneously. The interaction between cognitive and motor functions is vital for daily activities. Any disruption in this connection can lead to significant disabilities, including an increased risk of falls, which can severely impact a person's quality of life. However, despite the clear evidence that PwMS struggle with dual-tasking, there are limited therapeutic interventions that effectively utilize the dual-task paradigm to mitigate its consequences. A systematic review conducted by Plummer et al highlighted the impact of traditional physiotherapy dual-task training and the lack of cognitive-motor interaction in older adults, which limits the availability of evidence-based recommendations. The lack of dual task interaction in traditional physiotherapy approaches has been identified as a contributing factor to the suboptimal outcomes in improving mobility, cognitive function, and consequently the fall risks. The integration between cognitive-motor interaction in rehabilitation is crucial to achieve better outcomes to reduce fall risk. To address this gap, a rehabilitation program that specifically targets cognitive-motor interactions is warranted.

In the last few years, the use of gaming technology has emerged in the neurorehabilitation field with advancements in technology. Gaming technology provides subjects with task-oriented training, repetitive practice with high intensity, multi-sensory feedback information, and motivation for endurance practice. It offers a more accessible and cost-effective intervention compared to traditional physical therapy. However, few studies have investigated the effects of dual-task training using virtual reality (VR) in people with Multiple Sclerosis (PwMS). A recent systematic review (currently under review) found that VR dual-task training has shown weak effects. This may be due to previous studies utilizing generic VR games that were not tailored to the specific impairments associated with MS. Additionally, the immersive nature of VR may induce cyber sickness, causing discomfort similar to motion sickness.

In contrast to VR, Augmented Reality (AR) technology is emerging as a promising alternative in the field of rehabilitation. The use of AR in neurological rehabilitation has significantly expanded, offering a unique advantage by seamlessly combining motor and cognitive tasks. In AR, users interact with real environments enhanced by virtual objects relevant to daily activities, enabling effective motor-cognitive training with immediate feedback in a safe, controlled setting, crucial for improving rehabilitation outcomes. AR is also less overwhelming compared to other gaming technologies, as it does not provide a fully immersive experience, making it easier for patients who struggle with intense visual and sensory stimulation. Additionally, the flexibility of AR allows patients to engage in therapy at home, easily integrating it with everyday activities. This rehabilitation approach enhances the enjoyment of therapy, providing an interactive experience, which can improve long-term adherence, a vital factor for managing a progressive disease like MS, where maintaining function throughout all stages is essential. This project aims to support people with Long Term Neurological Conditions (LTNC) with complex needs as per MS to maintain mobility and cognitive function has potential to reduce dependence on residential services and acute hospital care. This proposed project also aligns with the National Multiple Sclerosis Society priorities and objectives which emphasize advancing innovative and emerging treatments that can slow and reverse MS. It has an important role to play in developing seamless programs for the management of people with LTNCs that focus on early intervention with better use of technology approaches in rehabilitation that can also form a sustainable resource to patient's self-management in the future.

Being tested
Augmented Reality Exercises
Keywords
dual task, rehabilitation, augmented reality, motor function
Medical subject headings
Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Augmented Reality ExercisesOther

    Also called AR dual task

    All participants in the experimental group will then be given a tutorial on how to perform the proposed exercises based on AR and they will be asked to familiarise themselves with the system. While the participants in the control group will be given a leaflet of physical exercises and they will be instructed by a physical therapist on the correct performance of these exercises

Study groups in NCT07434934
Study groupRoleWhat they receive
Augmented RealityActive comparatorThe participants in the experimental group will be asked to make 3 visits per week for a total of 18 sessions over the intervention period (6-week). Each session is expected to last between 40 minutes to one hour.
Receives: Other: Augmented Reality Exercises
Home-based exercisesNo interventionHome exercise control group will include the same exercises as in the intervention group except that they will perform at home for the same parameters without the utility of AR.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gait Velocity- single-task (BTS GAITLAB)

    Measured using BTS GAITLAB (Physiotherapy Laboratory, University of Sharjah) during walking under single-task condition (walking only). Report mean gait velocity across trials. Higher = faster walking.

    Measured: six weeks

  2. Gait velocity during dual-task walking (m/s)

    Measured using BTS GAITLAB during walking under dual-task cognitive condition. Report mean gait velocity across trials. Higher = faster walking under dual-task.

    Measured: 6 weeks

Secondary outcomes (18)
  1. Balance - Berg Balance Scale (BBS)

    Balance assessed using the Berg Balance Scale. Report total score (0-56). Higher = better balance.

    Measured: Six weeks

  2. Activities-specific Balance Confidence (ABC) Scale score (0-100%)

    Balance confidence assessed using the ABC scale. Report total/mean percentage score (0-100%). Higher = greater confidence.

    Measured: 6 weeks

  3. Five Times Sit-to-Stand test time (seconds)

    Functional lower-limb performance assessed using five times chair sit-to-stand test. Report completion time in seconds. Lower = better.

    Measured: 6 weeks

  4. Functional Mobility Scale (FMS) rating

    Functional mobility assessed using the Functional Mobility Scale. Report FMS rating (per standard scoring). Higher = better mobility.

    Measured: 6 weeks

  5. Biodex Balance System stability index (unit per device output)

    Instrumented balance assessed using the Biodex Medical Balance System (Physiotherapy Laboratory, University of Sharjah). Report stability index as provided by the device. Interpret direction as per device metric (lower = better stability).

    Measured: 6 weeks

  6. Daily step count measured by FIBION (steps/day)

    Physical activity assessed using FIBION activity monitor worn 7 consecutive days / 24 h before and after intervention. Report mean daily step count over the monitoring period. Higher = more activity.

    Measured: 6 weeks

  7. Modified Physical Activity Scale (M-PAS) score

    Self-reported physical activity assessed using M-PAS. Report total score (per instrument scoring). Specify direction per scoring (higher = more activity).

    Measured: 6 weeks

  8. Falls Efficacy Scale-International (FES-I) total score

    Fall concern assessed using FES-I. Report total score (per instrument scoring). Higher = greater concern about falling (worse).

    Measured: 6 weeks

  9. Modified Fatigue Impact Scale (MFIS) total score

    Fatigue assessed using MFIS. Report total score (per instrument scoring). Higher = worse fatigue impact.

    Measured: 6 weeks

  10. Short Form-36 (SF-36) health-related quality of life score

    Quality of life assessed using SF-36. Report domain scores and/or Physical and Mental Component Summary scores (per SF-36 scoring). Higher = better health status.

    Measured: 6 weeks

  11. Hospital Anxiety and Depression Scale (HADS-A) score (0-21)

    Anxiety symptoms assessed using HADS Anxiety subscale. Report subscale score (0-21). Higher = worse anxiety symptoms.

    Measured: 6 weeks

  12. Hospital Anxiety and Depression Scale (HADS-D) score (0-21)

    Depressive symptoms assessed using HADS Depression subscale. Report subscale score (0-21). Higher = worse depressive symptoms.

    Measured: 6 weeks

  13. 6-Minute Walk Test distance (meters)

    Physical performance assessed using the 6-minute walking test. Report distance walked in meters. Higher = better walking endurance.

    Measured: 6 weeks

  14. Montreal Cognitive Assessment (MoCA) total score (0-30)

    Global cognitive function assessed using the MoCA. Report total score (0-30). Higher = better cognition.

    Measured: 6 weeks

  15. Symbol Digit Modalities Test (SDMT) score (correct responses)

    Processing speed assessed using SDMT (BICAMS component). Report total correct responses (per scoring). Higher = better.

    Measured: 6 weeks

  16. Hopkins Verbal Learning Test-II (HVLT-II) total recall score

    Verbal learning/memory assessed using HVLT-II (BICAMS component). Report total recall score (per scoring). Higher = better.

    Measured: 6 weeks

  17. Brief Visuospatial Memory Test-Revised (BVMT-R) total recall score

    Visuospatial memory assessed using BVMT-R (BICAMS). Report total recall score (per scoring). Higher = better memory.

    Measured: 6 weeks

  18. Stroop test interference score (per protocol)

    Inhibitory control assessed using the Stroop test. Report interference score. lower interference score = better

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Feb 2026
  2. Study start1 Aug 2026 (estimated)
  3. Primary completion1 Mar 2028 (estimated)
  4. Study completion1 Sep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07434934
Sponsor's protocol ID
REC-24-12-22-01-F
Other IDs
133128
Acronym
MS
Status last verified
Feb 2026
First submitted
10 Feb 2026
Last updated
5 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Augmented Reality Exercises in people with Multiple Sclerosis, run by University of Sharjah at 1 site in United Arab Emirates.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Alham Al Sharman, Associate Prof (00971563103259, aal-sharman@sharjah.ac.ae), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gait Velocity- single-task (BTS GAITLAB) (time frame: six weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
MS Clinical Trial NCT07434934 | AzTrials